BANGOR, Mich., July 1, 2014 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (MBI) (Nasdaq:MBII), a leading global provider of bio-based pest management and plant health products, is celebrating the official opening of its Marrone Michigan Manufacturing (M3) facility today with a ribbon cutting ceremony and plant tours for invited guests.
Today's event features a facility tour which highlights the benefits of MBI's bio-based products for pest management and plant health and gives attendees a firsthand look at the updates and expansions to the production facility. Speakers at the ribbon cutting event include:
- Senator Debbie Stabenow, Chairwoman of the U.S. Senate Committee on Agriculture
- Administrator Lillian Salerno, USDA Rural Business-Cooperative Service
- Director James Turner, State Director, USDA-Rural Development
- Senator John Proos and Representative Aric Nesbitt, Michigan Senate and House of Representatives
- Mayor Nick Householder, Mayor of Bangor, Michigan
- Dr. Pamela Marrone, CEO and Founder, Marrone Bio Innovations
Live streaming of the speakers' comments and the ribbon cutting ceremony will be available at approximately 11:20 a.m. Eastern Standard Time. To see live streaming video of the event click here. Additional information will be available after the event. Those details will be provided after the conclusion of the event.
About Marrone Bio Innovations
Marrone Bio Innovations, Inc. (Nasdaq:MBII) is a leading provider of bio-based pest management and plant health products for the agriculture, turf and ornamental, and water treatment markets. Our effective and environmentally responsible solutions help customers operate more sustainably while controlling pests, improving plant health and increasing crop yields. We have a proprietary discovery process, a rapid development platform, and a robust pipeline of pest management and plant health product candidates. At Marrone Bio Innovations we are dedicated to pioneering better biopesticides that support a better tomorrow for users around the globe. For more information, please visit www.marronebio.com.
The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include statements regarding our expectations, beliefs,hopes, goals, intentions, initiatives or strategies, including statements relating to market size and the results from the field trials. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those in the forward-looking statements, including the difficulty in predicting the outcome of product research and development efforts and regulatory approvals. Additional relevant information concerning risks can be found in the in the Form 10-Q that the Company filed with the Securities and Exchange Commission on May 15, 2014.
Source:Marrone Bio Innovations